Alexander Mayweg Ph.D. was Chief Scientific Officer, Director of the Company. He has served as a member of our board of directors since March 2017 and, from March 2017 to September 2019, served as our interim Chief Scientific Officer. Dr. Mayweg has served as a Partner at Versant Ventures, a healthcare investment firm, since January 2018, and previously served as a Venture Partner at Versant Ventures from January 2017 to December 2017. Additionally, since April 2017, Dr. Mayweg has served as Chief Scientific Officer at Ridgeline Therapeutics, a Versant Ventures Discovery Engine that creates and operates Versant-financed biotechnology companies in Basel, Switzerland. Prior to joining Versant, from 2013 to 2016, Dr. Mayweg served as Vice President and Global Head of Medicinal Chemistry at F. Hoffmann-La Roche AG, a multinational healthcare company, and held various leadership positions at Roche in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S. and Asia. Dr. Mayweg graduated with a B.S. in Chemistry from the Imperial College in London and earned a Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University.
Alexander Mayweg is 45, he's been the Director of Black Diamond Therapeutics Inc since 2019. There are 14 older and 4 younger executives at Black Diamond Therapeutics Inc. The oldest executive at Black Diamond Therapeutics Inc is Robert Ingram, 77, who is the Independent Chairman of the Board.
Alexander's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah y Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include: